Trial Profile

Phase II Clinical Trial to Analyze the Safety and Efficacy of Vedolizumab Combined With Antiretroviral Therapy to Achieve Permanent Virological Remission in HIV-infected Subjects Without Previous Antiretroviral Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary) ; Dolutegravir; Emtricitabine/tenofovir alafenamide; Hydrocortisone
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use

16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
21 Nov 2021 Status changed from recruiting to completed.
22 Jun 2018 Planned End Date changed from 28 May 2020 to 1 May 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com